Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Equity Ratio (2017 - 2025)

Arcus Biosciences has reported Equity Ratio over the past 9 years, most recently at 0.55 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.55 for Q4 2025, up 31.36% from a year ago — trailing twelve months through Dec 2025 was 0.55 (up 31.36% YoY), and the annual figure for FY2025 was 0.55, up 31.36%.
  • Equity Ratio for Q4 2025 was 0.55 at Arcus Biosciences, up from 0.45 in the prior quarter.
  • Over the last five years, Equity Ratio for RCUS hit a ceiling of 0.71 in Q1 2021 and a floor of 0.42 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.51 (2022), compared with a mean of 0.51.
  • Biggest five-year swings in Equity Ratio: dropped 27.36% in 2022 and later surged 31.36% in 2025.
  • Arcus Biosciences' Equity Ratio stood at 0.53 in 2021, then dropped by 4.45% to 0.51 in 2022, then dropped by 16.52% to 0.42 in 2023, then fell by 0.04% to 0.42 in 2024, then skyrocketed by 31.36% to 0.55 in 2025.
  • The last three reported values for Equity Ratio were 0.55 (Q4 2025), 0.45 (Q3 2025), and 0.51 (Q2 2025) per Business Quant data.